Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2014, specifically dated September 5, 2014. The registrant is a foreign private issuer based in Petach-Tikva, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The primary material event disclosed is the issuance of a Japanese patent for the company's drug candidate, CF102. This patent covers the treatment of liver regeneration and function following liver surgery or other injury.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, specific risk factors, or contingencies beyond the regulatory milestone achieved. The document serves solely to incorporate a press release regarding the patent grant.
Investor Verification Points
- Verify the scope and validity of the Japanese patent for CF102 regarding liver regeneration.
- Confirm the commercialization strategy and regulatory pathway for CF102 in the Japanese market.
- Review the attached press release (Exhibit 99.1) for additional details on the patent's specific claims.